Clinical Trial Update: Open-label Long Term (52 Weeks) Safety and Tolerability of Agomelatine Sublingual Tablets in Major Depressive Disorder (MDD) [Phase 3]

View source ↗

Summary

Open-label long-term safety and tolerability study (52 weeks) of agomelatine sublingual tablets in major depressive disorder has terminated after a Phase 3 tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• agomelatine sublingual tablets (agomelatine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Major Depressive Disorder | Phase 3 | Status: TERMINATED